Top Dividend Aristocrat Stocks to Buy Are Growing Revenues 10% per Year
The Dividend Aristocrat stocks give investors the kind of long-term safety many are looking for now.
The Dividend Aristocrat stocks give investors the kind of long-term safety many are looking for now.
The potential for Federal Reserve rate hikes have continued to weigh on gold, keeping it boxed in a trading range. One top Wall Street analyst feels that the floor is in and the price…
SunTrust Robinson Humphrey feels that the demand trends for the top oilfield services companies remain solid and investors should advantage of the current weakness and buy the dip.
The revolution in data networking will only continue to grow as consumer and business demand for all Internet of Things and beyond continues to manifest.
With the defense sector underperforming recently, Merrill Lynch focuses on four companies that look like great stocks to add now.
In this week's top stock picks from Jefferies, three very prominent biotechnology stocks are featured, including one that is a large cap leader.
Merrill Lynch has raised price targets on four blue chip companies that have posted some outstanding numbers. These stocks are a good fit for growth-oriented portfolios that have a higher degree of risk tolerance.
Giddy investors continued pouring money into U.S. stocks last week, and insiders continued their steady purchases at companies where they work or have a large position on file.
Insiders are selling gigantic amounts of stock each and every week, and as long as we stay at these lofty levels, that probably will continue.
Here are three biotech companies that not only have data that could prove to be huge, but their shares have been absolutely hammered over the last year, offering aggressive accounts the best entry points…
Merrill Lynch’s outstanding semiconductor analyst Vivek Arya has focused his attention on three mid-cap companies that he feels could be outstanding stocks to own.
While things for 2017 actually look solid, and earnings actually should improve, the bottom line is we are way overbought and need a sell-off to take some of the air out.
Thursday’s top analyst upgrades, downgrades and initiations include Activision Blizzard, Anheuser-Busch, Amphenol, Biogen, Goldman Sachs BDC and Pure Storage.
Each year, the analysts at RBC come out with a detailed list of smaller companies they feel are targets for acquisitions. These four health care candidates look extremely attractive.
In an incredible analyst call, one of the top firms on Wall Street sees chip giant and industry leader Intel getting absolutely hammered by new competition, with shares set to fall sharply.
Wednesday’s top analyst upgrades, downgrades and initiations include Abbott Labs, General Dynamics, Nexstar Media, Owens Corning, Palo Alto Networks and Salesforce.com.
Baird points out that the natural gas liquids silo of the energy sector proved to be the bright spot in fourth-quarter results. These four stocks have big upside and solid NGL production.
While the logic to own consumer staples shares is that we all have to buy the necessities that go with day-to-day living, there are also reasons to avoid the sector.
Tuesday’s top analyst upgrades, downgrades and initiations include Apple, CVS Health, Priceline, Teva Pharmaceutical and Workday.
These five top companies havehit some economic potholes but are primed for a comeback. They all are well known, make a variety of consumer and commercial products and will be around in the future.